PTBP1-mediated repression of neuron-specific CDC42 splicing constitutes a genomic alteration-independent,

Junjie Yang1, Jing Feng2, Jing Lv1

  • 1Department of Biology, Beijing Key Laboratory of Gene Resource and Molecular Development, and Key Laboratory of Cell Proliferation and Regulation Biology, Ministry of Education, School of Life Sciences , Beijing Normal University, Beijing, China.

PubMed

Insights

New research identifies polypyrimidine tract-binding protein 1 (PTBP1) as a key vulnerability in IDH-wildtype glioblastoma (GBM). PTBP1 regulates splicing, impacting cell survival and offering a potential therapeutic target independent of genomic alterations.

Area of Science:

  • Neuro-oncology
  • Molecular biology
  • Genomics

Background:

  • Gene co-expression networks offer insights into adult glioma vulnerabilities.
  • An EM/PM classification scheme categorizes gliomas based on conserved gene modules and cellular origin.

Purpose of the Study:

  • To identify EM/PM subtype-specific gene co-expression networks.
  • To characterize polypyrimidine tract-binding protein 1 (PTBP1) as a vulnerability in IDH-wildtype glioblastoma (GBM).

Main Methods:

  • Weighted gene co-expression network analysis (WGCNA) to identify subtype-specific modules.
  • Lentiviral vector-mediated knockdown of PTBP1 in IDH-wildtype GBM cells.
  • Analysis of PTBP1-dependent splicing patterns and CDC42-N isoform expression.

Main Results:

  • Adult gliomas were assigned into 4 prognostically relevant gene co-expression modules.
  • The EM subtype showed modules related to splicing, DNA replication, and immune cells; the PM subtype showed modules for transcriptional regulation and mRNA translation.
  • PTBP1 was identified as a key hub gene in the EM subtype, repressing the splicing of CDC42-N, which impacts cell survival.

Conclusions:

  • PTBP1-mediated repression of CDC42-N splicing is a potential genomic alteration-independent vulnerability in IDH-wildtype GBM.
  • This finding highlights conserved, developmentally relevant therapeutic targets in adult gliomas.